Aims: Pretherapy serum neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and lymphocyte to monocyte ratio have been shown to predict prognosis in patients with pancreatic ductal adenocarcinoma (PDAC). The aim of this study was to evaluate whether NLR, PLR and LMR help in predicting survival outcomes in patients with PDAC treated with curative intent surgery and chemotherapy at our center. Methods: A retrospective analysis was done of all operated cases of PDAC who underwent curative resection between 2011 to 2018. The pretherapy NLR, PLR and LMR were calculated and analyzed with respect to pathological and survival outcomes Results: 134 operated patients of PDAC were included in the analysis. 94 patients were operated upfront and 40 following neoadjuvant chemotherapy. The median overall survival and disease free survival was 24 months and 17 months respectively. The 1 and 2-year survival was 77.2% and 48% respectively. The Overall survival for NLR values of less than 2, 2.7 and 5 was 27, 25 and 25 months and for NLR more than 2, 2.7 and 5 was 22, 18 and 17 months respectively and was statistically insignificant . Similarly, the PLR and LMR were not significant for a cut off of 150 and 2.8 respectively. On univariate analysis only stage of disease was found to have significant correlation with survival Conclusions: The NLR, PLR and LMR do not correlate with survival in patients with pancreatic ductal adenocarcinomas in this study.